Skip to content
The Policy VaultThe Policy Vault

NucalaMedical Mutual

Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)

Initial criteria

  • Patient age ≥ 18 years; AND
  • Has active, non-severe disease (vasculitis without life-/organ-threatening manifestations); AND
  • Currently receiving systemic corticosteroid (≥ 4 weeks); AND
  • Blood eosinophil ≥ 150 cells/µL within previous 6 weeks OR prior to treatment with antibody therapy that may lower eosinophils; AND
  • Prescribed by/consult allergist, immunologist, pulmonologist, or rheumatologist

Reauthorization criteria

  • Already received ≥ 6 months of Nucala; AND
  • Responded to therapy as determined by prescriber (e.g., reduced relapse, corticosteroid dose reduction, reduced eosinophil levels)

Approval duration

6 months initial; 1 year reauth